Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension

Mayo Clinic Proceedings

Volumn 87, Issue 4, 2012, Pages 413-415

  Cataliotti, Alessandro ^a   Costello Boerrigter, Lisa C ^a   Chen, Horng H ^a   Textor, Stephen C ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN; NESIRITIDE;

ADULT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CASE REPORT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LETTER; LOW DRUG DOSE; MALE; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 84859876302     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.02.003     Document Type: Letter

References (5)

1. Belluardo P, Cataliotti A, Bonaiuto L, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291(4):H1529- H1535. (Pubitemid 44497655)
2. Cataliotti A, Macheret F, McKie P, et al. Deficiency of the cardiorenal protective hormone BNP in early stages of hypertension [abstract]. J Hypertens. 2010;28:e21.
3. Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112(6):836-840. (Pubitemid 41170069)
4. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011;123(12):1297- 1305.
5. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10(2): 115-119. (Pubitemid 38858071)